导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.15% | 1933/4773 |
| 近一周 | -2.32% | 1795/5462 |
| 近一月 | -3.68% | 1904/5421 |
| 近一季 | -6.89% | 2228/5209 |
| 近半年 | -1.33% | 1554/4920 |
| 近一年 | 4.16% | 1780/4366 |
| 近两年 | 51.41% | 1430/2954 |
| 近三年 | 30.87% | 1020/2253 |
| 成立以来 | 218.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.65% 2408/4961 |
11.76% 2299/5312 |
- - |
- - |
| 2025 | 22.51% 1964/4813 |
0.45% 1845/3635 |
2.20% 1770/4076 |
18.05% 2359/4524 |
1.09% 1546/4813 |
| 2024 | 14.07% 1078/3463 |
2.14% 811/2808 |
-0.71% 823/3014 |
15.00% 1846/3129 |
-2.20% 1999/3463 |
| 2023 | -14.40% 1599/2656 |
1.25% 1611/2280 |
-5.77% 1529/2385 |
-3.60% 960/2515 |
-6.93% 1985/2655 |
| 2022 | -21.23% 1021/2207 |
-15.73% 1064/1919 |
8.70% 334/2016 |
-15.08% 1208/2113 |
1.26% 1320/2208 |
| 2021 | -3.02% 883/1822 |
-5.34% 917/1255 |
7.56% 681/1330 |
-6.49% 939/1466 |
1.87% 770/1822 |
| 2020 | 34.27% 442/1250 |
-7.91% 579/1028 |
16.04% 461/1067 |
12.82% 361/1164 |
11.37% 546/1184 |
| 2019 | 37.28% 339/1092 |
25.96% 433/754 |
1.34% 136/804 |
1.15% 428/850 |
6.33% 625/918 |
| 2018 | -23.16% 270/834 |
- - |
- - |
- - |
-12.31% 433/691 |
| 2017 | 29.84% 62/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.82% 120/605 |
- - |
- - |
- - |
- - |
| 2015 | 12.67% 152/575 |
- - |
- - |
- - |
- - |
| 2014 | 55.94% 51/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.71% 80/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达沪深300量化增强 VS. 长安沪深300非周期A(740101) |